Drug Trial News

RSS
FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

17 Feb 2011
Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

17 Feb 2011
Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer

Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer

17 Feb 2011
Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

16 Feb 2011
Endologix announces initial PEVAR Trial presentation at 2011 iCON annual meeting

Endologix announces initial PEVAR Trial presentation at 2011 iCON annual meeting

16 Feb 2011
Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

16 Feb 2011
The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

From Baxter International Inc. 15 Feb 2011
Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

15 Feb 2011
Almac's Director plans to speak on adaptive trial designs at CTS Europe conference

Almac's Director plans to speak on adaptive trial designs at CTS Europe conference

15 Feb 2011
Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

15 Feb 2011
Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

15 Feb 2011
Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency

Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency

14 Feb 2011
FDA waives NDA filing fee for Antares' Anturol NDA

FDA waives NDA filing fee for Antares' Anturol NDA

14 Feb 2011
FDA grants BrainStorm's NurOwn orphan drug designation for treatment of ALS

FDA grants BrainStorm's NurOwn orphan drug designation for treatment of ALS

14 Feb 2011
Neoprobe achieves accrual goal in Lymphoseek Phase 3 study in breast cancer/melanoma

Neoprobe achieves accrual goal in Lymphoseek Phase 3 study in breast cancer/melanoma

14 Feb 2011
Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis

Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis

14 Feb 2011
OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

14 Feb 2011
Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

14 Feb 2011
Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

14 Feb 2011
SynthRx to become wholly-owned subsidiary of ADVENTRX

SynthRx to become wholly-owned subsidiary of ADVENTRX

14 Feb 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback